Sai Parenterals Limited (SAIPARENT) — Financial Results | 12 August 2026

12 August 2026 · NSE 🔴 High Importance Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Sai Parenterals announces acquisition of 60% stakes in Saicriti Pharma and Prathyak Laboratories to expand injectable capacity and R&D capabilities.

🔄 What Changed

Export revenue share increased from 3% (FY23) to 63% (FY26); injectable capacity increased by 47% to 154.66 million units annually; FY27 EBITDA margin target set at 17% with ₹750 crore revenue goal.

🔮 What's Next

New injectable facility completion by April 2027; R&D centre operational by 30 September 2027; FY27 revenue target of ₹750 crore and 17% EBITDA margin; FY28 monetization focus.

💡 Investor Takeaway

The acquisitions and facility upgrades are designed to significantly boost export revenue and injectable production capacity, supporting higher-margin growth and improved profitability targets by FY27.

Sai Parenterals Limited reported FY26 revenue of [amount context mismatch] crore with a 17% EBITDA margin target for FY27, driven by export revenue rising to 63% of total and strategic acquisitions of Saicriti Pharma and Prathyak Laboratories. The company secured AUD 27 million in Australia and USD 11 million in the Philippines, while expanding injectable capacity by 47% to 154.66 million units annually through a new facility slated for completion in April 2027. Capex of ₹571 crore is allocated to acquisitions and facility upgrades, with FY27 revenue growth accelerating to 175% YoY in Q1.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SAIPARENT ✨ Ask AI About This

About Sai Parenterals Limited (SAIPARENT)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹2,335.98 CrP/E: 142.9ROE: 3.2%ROCE: 4.6%

View full SAIPARENT stock details →

📡 Get AI alerts when SAIPARENT files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SAIPARENT — Free

💡 Ask AI about this filing

"What is the valuation multiple for the Saicriti and Prathyak acquisitions?""How will the new injectable capacity be utilized to meet revenue targets?""What is the expected EBITDA margin contribution from the Adelaide facility?"

Ask AI Free →

📊 More SAIPARENT filings

🔴 Announcement — 1 October 2026Sai Parenterals Ltd announced a scheduled investor and analyst meeting in Hyderabad on October 14, 2...
🟡 Board Meeting — 30 September 2026Sai Parenterals announced board approval of Ms. Shivali Aggarwal's resignation as Company Secretary ...
Announcement — 30 September 2026Sai Parenterals Ltd announced that its trading window will close on 1 October 2026 and remain shut u...
🟡 Board Meeting — 30 September 2026Sai Parenterals announced board approval of Ms. Shivali Aggarwal's resignation effective 30 Septembe...
🟡 Voting Results — 10 September 2026Sai Parenterals held its AGM on 10 September 2026 via video conference, approving all 12 proposed re...

See all SAIPARENT filings →

🔥 Also filed on 12 August 2026

DBLDilip Buildcon LimitedCorporate Action NITCONitco LimitedFinancial Results KPIGREENKPI Green Energy LimitedFinancial Results SDBLSom Distilleries & Breweries LimitedFinancial Results CONSOFINVTConsolidated Finvest & Holdings LimitedCorporate Action TOUCHWOODTouchwood Entertainment LimitedFinancial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SAIPARENT files new disclosures

Track SAIPARENT filings, board meetings, and corporate actions. Free email alerts at 5 PM.